



## **ASX Announcement**

**8 February 2021**

### **Statement pursuant to ASX Listing Rule 4.7C.2**

MELBOURNE, AUSTRALIA (8 February 2021): Hexima Limited (ASX:HXL) advises that in accordance with ASX Listing Rule 4.7C.2, it has today filed a comparison of actual expenditure incurred during the quarter ended 31 December 2020, against the “Use of Proceeds” as set out on page 10 of Hexima’s Prospectus dated 15 October 2020. This detail can be found in Appendix One, attached to this announcement.

#### **About Hexima**

Hexima is a biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally. For additional information about Hexima please visit [www.hexima.com.au](http://www.hexima.com.au).

**This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & Chief Executive Officer**

#### ***Enquiries:***

Dr Nicole van der Weerden

Chief Operating Officer

[n.vanderweerden@hexima.com.au](mailto:n.vanderweerden@hexima.com.au)

***Join our email database to receive company announcements:***

[Info@hexima.com.au](mailto:Info@hexima.com.au)

[www.hexima.com.au](http://www.hexima.com.au)

## APPENDIX ONE

Use of Proceeds as set out on page 10 of Hexima's Prospectus dated 15 October 2020			
Categories	Expected Use of Proceeds \$000's	Actual cash spent from 1 October 2020 to 31 December 2020 \$000's	% of total
Phase IIb clinical trial	3,400	414	12
Scale-up of HXP124 manufacture and production of material for toxicology studies	1,200	522	43
Formulation, stability and chemistry, manufacture and controls	700	227	32
Toxicology studies	2,000	0	0
Market research	100	15	15
Costs of the offer	700	689	98
Working capital	2,300	942	41
<b>Totals</b>	<b>10,400</b>	<b>2,809</b>	<b>27</b>

### Notes:

1. The amounts included in the Use of Proceeds table above exclude cash received from the R&D tax incentive and lease revenue during this period.